2023
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease
Kirk F, Munk D, Swenson E, Quicquaro A, Vendelbo M, Larsen A, Schilsky M, Ott P, Sandahl T. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. Journal Of Hepatology 2023, 80: 586-595. PMID: 38081365, DOI: 10.1016/j.jhep.2023.11.023.Peer-Reviewed Original ResearchEffect of tetrathiomolybdateWilson's diseaseBiliary copper excretionBiliary excretionHealthy volunteersCopper excretionWD patientsBis-choline tetrathiomolybdateNeurologic Wilson diseaseClinical trial numberPresent human studyTrial numberPET/CTCopper metabolismIntestinal copper uptakeMechanism of actionPET/MRINeurological worseningConventional therapyVenous bloodClinical trialsLower riskAnimal studiesHuman studiesCopper chelator
2008
Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease
Brewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. 2008, 153-166. DOI: 10.1017/cbo9780511666971.010.Peer-Reviewed Original ResearchTypes of patientsWilson's diseaseMaintenance therapyInitial treatmentZinc maintenance therapyDouble-blind trialOpen-label studyNeurologic Wilson diseaseWeeks of treatmentDouble-blind designAnticopper drugNeurologic worseningTM armNeurologic deteriorationIntolerant patientsMost patientsNeurologic presentationNeurologic symptomsIll patientsSuch patientsUrine studiesBlind designBlind trialPatientsLabel study